

MAGE - A2 (157 - 166)
Synthetic Peptide
Catalog # SP2473a**Specification**

MAGE - A2 (157 - 166) - Product InformationPrimary Accession
Sequence[P43356](#)
NH2-YLQLVFGIEV-COOH**MAGE - A2 (157 - 166) - Additional Information****Gene ID** 266740;4101**Other Names**

Melanoma-associated antigen 2, Cancer/testis antigen 12, CT12, MAGE-2 antigen, MAGEA2, MAGE2, MAGEA2A

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

MAGE - A2 (157 - 166) - Protein Information**Name** MAGEA2**Synonyms** MAGE2, MAGEA2A**Function**

Reduces p53/TP53 transactivation function through recruitment of HDAC3 to p53/TP53 transcription sites. Also represses p73/TP73 activity. Proposed to enhance ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases. In vitro enhances ubiquitin ligase activity of TRIM28 and stimulates p53/TP53 ubiquitination by TRIM28 potentially in presence of Ubl-conjugating enzyme UBE2H. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzyme (E2) at the E3:substrate complex. May play a role in embryonal development and tumor transformation or aspects of tumor progression. In vitro promotes cell viability in melanoma cell lines. Antigen recognized on a melanoma by autologous cytolytic T-lymphocytes. Negatively regulates acetylation and sumoylation of PML and represses PML-induced p53/TP53 acetylation and activation.

Cellular Location

Nucleus. Nucleus, PML body.

Tissue Location

Expressed in many tumors of several types, such as melanoma, head and neck squamous cell carcinoma, lung carcinoma and breast carcinoma, but not in normal tissues except for testes

MAGE - A2 (157 - 166) - Images